Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 151

1.

Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies.

Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, Pope JE, Steinhart AH, Vinh DC, Wade J.

J Cutan Med Surg. 2018 Nov 21:1203475418811335. doi: 10.1177/1203475418811335. [Epub ahead of print]

PMID:
30463418
2.

Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study.

Haraoui B, Jamal S, Ahluwalia V, Fung D, Manchanda T, Khraishi M.

Rheumatol Ther. 2018 Dec;5(2):551-565. doi: 10.1007/s40744-018-0130-6. Epub 2018 Oct 28.

3.

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.

Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Pinto-Correia A, Otawa S, Lopez-Romero P, de la Torre I, Macias W, Rooney TP, Smolen JS.

Ann Rheum Dis. 2019 Feb;78(2):171-178. doi: 10.1136/annrheumdis-2018-213271. Epub 2018 Sep 7.

4.

A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.

Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R.

Semin Arthritis Rheum. 2018 Dec;48(3):406-415. doi: 10.1016/j.semarthrit.2018.07.006. Epub 2018 Jul 19.

5.

High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years.

Barber CEH, Schieir O, Lacaille D, Marshall DA, Barnabe C, Hazlewood G, Thorne JC, Ahluwalia V, Bartlett SJ, Boire G, Haraoui B, Hitchon C, Keystone E, Tin D, Pope JE, Denning L, Bykerk VP; Canadian Early Arthritis Cohort Investigators.

Arthritis Care Res (Hoboken). 2018 Jun;70(6):842-850. doi: 10.1002/acr.23439. Epub 2018 Mar 25.

6.

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study.

Thorne C, Boire G, Chow A, Garces K, Liu F, Poulin-Costello M, Walker V, Haraoui B.

Open Rheumatol J. 2017 Oct 24;11:123-135. doi: 10.2174/1874312901711010123. eCollection 2017.

7.

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.

Curtis JR, Winthrop K, O'Brien C, Ndlovu MN, de Longueville M, Haraoui B.

Arthritis Res Ther. 2017 Dec 15;19(1):276. doi: 10.1186/s13075-017-1466-y.

8.

Defining and characterizing sustained remission in patients with rheumatoid arthritis.

Curtis JR, Trivedi M, Haraoui B, Emery P, Park GS, Collier DH, Aras GA, Chung J.

Clin Rheumatol. 2018 Apr;37(4):885-893. doi: 10.1007/s10067-017-3923-z. Epub 2017 Dec 9.

9.

Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.

Schulman E, Bartlett SJ, Schieir O, Andersen KM, Boire G, Pope JE, Hitchon C, Jamal S, Thorne JC, Tin D, Keystone EC, Haraoui B, Goodman SM, Bykerk VP; CATCH Investigators.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1185-1191. doi: 10.1002/acr.23457. Epub 2018 Jul 13.

PMID:
29193840
10.

Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis.

Nagaraj S, Barnabe C, Schieir O, Pope J, Bartlett SJ, Boire G, Keystone E, Tin D, Haraoui B, Thorne JC, Bykerk VP, Hitchon C; Canadian Early Arthritis Cohort Study Investigators.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1245-1250. doi: 10.1002/acr.23470.

PMID:
29125904
11.

Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry.

Rahman P, Zummer M, Bessette L, Baer P, Haraoui B, Chow A, Kelsall J, Kapur S, Rampakakis E, Psaradellis E, Lehman AJ, Nantel F, Osborne B, Tkaczyk C.

BMJ Open. 2017 Aug 30;7(8):e016619. doi: 10.1136/bmjopen-2017-016619.

12.

Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies.

Haraoui B, Casado G, Czirják L, Taylor A, Bernasconi C, Reiss W, Caporali R.

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):899-906. Epub 2017 Apr 28.

PMID:
28516886
13.

Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis.

Kuriya B, Schieir O, Lin D, Xiong J, Pope J, Boire G, Haraoui B, Thorne JC, Tin D, Hitchon C, Jamal S, Keystone E, Bykerk VP; CATCH Investigators.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):799-803. Epub 2017 Mar 23.

PMID:
28339365
14.

The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis.

Barra LJ, Pope JE, Hitchon C, Boire G, Schieir O, Lin D, Thorne CJ, Tin D, Keystone EC, Haraoui B, Jamal S, Bykerk VP; CATCH group.

Rheumatology (Oxford). 2017 May 1;56(5):768-776. doi: 10.1093/rheumatology/kew474.

PMID:
28073956
15.

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.

Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R.

Lancet. 2016 Dec 3;388(10061):2763-2774. doi: 10.1016/S0140-6736(16)31651-8. Epub 2016 Nov 15. Erratum in: Lancet. 2017 Feb 4;389(10068):e2.

PMID:
27863807
16.

Predicting Low Disease State and Remission in Early Rheumatoid Arthritis in the First Six Months, Comparing the Simplified Disease Activity Index and European League Against Rheumatism Response Measures: Results From an Early Arthritis Cohort.

Omair MA, Keystone E, Bykerk V, Lin D, Xiong J, Sun Y, Boire G, Thorne JC, Tin D, Pope J, Hitchon C, Haraoui B, Akhavan PS; Canadian Early Arthritis Cohort Investigators.

Arthritis Care Res (Hoboken). 2017 May;69(5):737-741. doi: 10.1002/acr.22983. Epub 2017 Apr 7.

17.

Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort.

Hitchon CA, Boire G, Haraoui B, Keystone E, Pope J, Jamal S, Tin D, Thorne C, Bykerk VP; CATCH investigators.

Rheumatology (Oxford). 2016 Oct;55(10):1751-62. doi: 10.1093/rheumatology/kew061. Epub 2016 Jun 21.

PMID:
27330161
18.

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set.

Bykerk VP, Bingham CO, Choy EH, Lin D, Alten R, Christensen R, Furst DE, Hewlett S, Leong A, March L, Woodworth T, Boire G, Haraoui B, Hitchon C, Jamal S, Keystone EC, Pope J, Tin D, Thorne JC, Bartlett SJ.

RMD Open. 2016 May 26;2(1):e000225. doi: 10.1136/rmdopen-2015-000225. eCollection 2016.

19.

Limitations in the Full Reporting of Systematic Literature Review.

Haraoui B.

J Rheumatol. 2016 May;43(5):994. doi: 10.3899/jrheum.151175. No abstract available.

PMID:
27134279
20.

Dr. Roubille, et al reply.

Roubille C, Richer V, Starnino T, McCourt C, McFARLANE A, Fleming P, Siu S, Kraft J, Lynde C, Pope JE, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

J Rheumatol. 2016 May;43(5):993-4. doi: 10.3899/jrheum.151347. No abstract available.

PMID:
27134278

Supplemental Content

Loading ...
Support Center